
    
      This study evaluates the efficacy, safety, and tolerability of ustekinumab in participants
      with active SLE according to Systemic Lupus International Collaborating Clinics (SLICC)
      criteria Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score greater
      than (>=) 6, despite receiving one or more standard-of-care treatments (example,
      immunomodulators, antimalarial drugs, and/or glucocorticoids). The total duration of the
      study is up to 182 weeks, consisting of 3 study periods: a screening period (approximately 6
      weeks), a double blind period (52 weeks), and an extension period (124 weeks). Other study
      evaluations will include pharmacokinetics, immunogenicity, biomarkers and pharmacogenomic
      evaluations. The safety of the participants enrolled in the study will be monitored on an
      ongoing basis throughout the study.
    
  